Evaluating the Safety and Efficacy of TLD in Patients With COPD

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
COPDChronic Obstructive Pulmonary Disease
Interventions
DEVICE

Targeted Lung Denervation (TLD)

Targeted Lung Denervation (TLD)Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.

DRUG

Standard medical care

Continuing standard of care COPD maintenance medication that minimally includes LABA/ICS, LAMA/LABA or LABA/LAMA/ICS.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

Temple Health

UNKNOWN

collaborator

Ohio State University

OTHER

collaborator

Honor Health - Clinical Trials

UNKNOWN

collaborator

Medical College of Wisconsin

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

lead

Nuvaira, Inc.

INDUSTRY